Literature DB >> 29327262

Risk of Neoplastic Progression Among Patients with an Irregular Z Line on Long-Term Follow-Up.

David Itskoviz1,2, Zohar Levi3,4, Doron Boltin3,4, Alex Vilkin3,4, Yifat Snir3,4, Rachel Gingold-Belfer3,4, Yaron Niv3,4, Iris Dotan3,4, Ram Dickman3,4.   

Abstract

BACKGROUND: Barrett's esophagus (BE) is a known complication of gastroesophageal reflux disease. In a previous study, we described a high prevalence of intestinal metaplasia (IM) in patients with an irregular Z line. However, the clinical importance of this finding is unclear. GOALS: To evaluate the long-term development of BE and relevant complications in patients diagnosed with an irregular Z line, with or without IM, on routine esophago-gastro-duodenoscopy (EGD).
METHODS: In our previously described cohort, 166 out of 2000 consecutive patients were diagnosed with an incidental irregular Z line. Of those with irregular Z line, 43% had IM. In this continuation study, patients' status was reassessed after a median follow-up of 70 months. Patients were divided into two groups: Patients with IM (IM-positive group) and without IM (IM-negative group). The incidence of long-term development of BE, dysplasia, and esophageal adenocarcinoma were compared between groups.
RESULTS: At least one follow-up EGD was performed in 102 (61%) patients with an irregular Z line. Endoscopic evidence of BE was found in eight IM-positive patients (8/50 [16%]) and in one IM-negative patient (1/52 [1.9%]). Two (4%) IM-positive patients developed BE with low-grade dysplasia. None of the patients developed high-grade dysplasia, or esophageal adenocarcinoma.
CONCLUSIONS: Patients with irregular Z line do not develop major BE complication in more than 5 years of follow-up.

Entities:  

Keywords:  Barrett’s esophagus; Dysplasia; Esophageal carcinoma; Irregular Z line

Mesh:

Year:  2018        PMID: 29327262     DOI: 10.1007/s10620-018-4910-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  American Gastroenterological Association medical position statement on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

2.  Comparative study of intestinal metaplasia and mucin staining at the cardia and esophagogastric junction in 225 symptomatic patients presenting for diagnostic open-access gastroscopy.

Authors:  J P Byrne; S Bhatnagar; B Hamid; G R Armstrong; S E Attwood
Journal:  Am J Gastroenterol       Date:  1999-01       Impact factor: 10.864

3.  Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study.

Authors:  Kee Wook Jung; Nicholas J Talley; Yvonne Romero; David A Katzka; Cathy D Schleck; Alan R Zinsmeister; Kelly T Dunagan; Lori S Lutzke; Tsung-Teh Wu; Kenneth K Wang; Mary Frederickson; Debra M Geno; G Richard Locke; Ganapathy A Prasad
Journal:  Am J Gastroenterol       Date:  2011-04-12       Impact factor: 10.864

4.  Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.

Authors:  Bas Weusten; Raf Bisschops; Emanuel Coron; Mário Dinis-Ribeiro; Jean-Marc Dumonceau; José-Miguel Esteban; Cesare Hassan; Oliver Pech; Alessandro Repici; Jacques Bergman; Massimiliano di Pietro
Journal:  Endoscopy       Date:  2017-01-25       Impact factor: 10.093

5.  Prospective evaluation of intestinal metaplasia and dysplasia within the cardia of patients with Barrett's esophagus.

Authors:  A P Weston; P T Krmpotich; R Cherian; A Dixon; M Topalovski
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

6.  Predictors of specialized intestinal metaplasia in patients with an incidental irregular Z line.

Authors:  Ram Dickman; Zohar Levi; Alex Vilkin; Ibrahim Zvidi; Yaron Niv
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-02       Impact factor: 2.566

Review 7.  Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction.

Authors:  Manuel Pera
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

8.  Prevalence of metaplasia at the gastro-oesophageal junction.

Authors:  S J Spechler; J M Zeroogian; D A Antonioli; H H Wang; R K Goyal
Journal:  Lancet       Date:  1994-12-03       Impact factor: 79.321

9.  ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.

Authors:  Nicholas J Shaheen; Gary W Falk; Prasad G Iyer; Lauren B Gerson
Journal:  Am J Gastroenterol       Date:  2015-11-03       Impact factor: 10.864

10.  British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.

Authors:  Rebecca C Fitzgerald; Massimiliano di Pietro; Krish Ragunath; Yeng Ang; Jin-Yong Kang; Peter Watson; Nigel Trudgill; Praful Patel; Philip V Kaye; Scott Sanders; Maria O'Donovan; Elizabeth Bird-Lieberman; Pradeep Bhandari; Janusz A Jankowski; Stephen Attwood; Simon L Parsons; Duncan Loft; Jesper Lagergren; Paul Moayyedi; Georgios Lyratzopoulos; John de Caestecker
Journal:  Gut       Date:  2013-10-28       Impact factor: 23.059

View more
  3 in total

1.  IMportance of an Irregular Z Line: Is Barrett's in the Eye of the Beholder?

Authors:  Swathi Eluri; Nicholas J Shaheen
Journal:  Dig Dis Sci       Date:  2018-06       Impact factor: 3.199

Review 2.  Mechanisms and pathophysiology of Barrett oesophagus.

Authors:  Rhonda F Souza; Stuart J Spechler
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-06-07       Impact factor: 73.082

Review 3.  Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges.

Authors:  Amrit K Kamboj; David A Katzka; Prasad G Iyer
Journal:  Gastrointest Endosc Clin N Am       Date:  2020-10-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.